QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial

Teladoc Health (TDOC) Stock Forecast & Price Target

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free tdoc Stock Alerts
$12.98
-0.20 (-1.52%)
(As of 04:10 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Teladoc Health Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$22.23
71.27% Upside
High Forecast$29.00
Average Forecast$22.23
Low Forecast$17.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
7 Buy rating(s)
Hold
7 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
19 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$22.23$22.43$26.60$34.00
Predicted Upside71.27% Upside29.30% Upside16.90% Upside6.08% Upside
Get Teladoc Health Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.

TDOC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TDOC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Teladoc Health Stock vs. The Competition

TypeTeladoc HealthMedical CompaniesS&P 500
Consensus Rating Score
2.46
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside68.67% Upside927.21% Upside12.32% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/5/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingHold
3/6/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$23.00 ➝ $17.00+17.89%
2/29/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageOverweight$22.00+45.79%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingMarket Perform
2/26/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Perform$17.00+17.24%
2/21/2024DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$22.00 ➝ $18.00+17.19%
2/21/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$21.00 ➝ $19.00+23.46%
2/21/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$26.00 ➝ $25.00+61.81%
2/21/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$30.00 ➝ $25.00+61.81%
2/21/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$30.00 ➝ $25.00+56.25%
2/21/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$34.00 ➝ $28.00+36.59%
11/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$33.00 ➝ $19.00+11.70%
10/25/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$35.00 ➝ $26.00+52.58%
10/11/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$25.00 ➝ $19.00-2.41%
4/28/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
4/28/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$27.00 ➝ $29.00+9.06%
4/27/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains
4/27/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:49 PM ET.

TDOC Price Target - Frequently Asked Questions

What is Teladoc Health's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Teladoc Health stock is Hold based on the current 7 hold ratings and 6 buy ratings for TDOC. The average twelve-month price prediction for Teladoc Health is $22.23 with a high price target of $29.00 and a low price target of $17.00. Learn more on TDOC's analyst rating history.

Do Wall Street analysts like Teladoc Health more than its competitors?

Analysts like Teladoc Health less than other Medical companies. The consensus rating for Teladoc Health is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how TDOC compares to other companies.

Does Teladoc Health's stock price have much upside?

According to analysts, Teladoc Health's stock has a predicted upside of 33.89% based on their 12-month stock forecasts.

What analysts cover Teladoc Health?

Teladoc Health has been rated by Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, DA Davidson, Leerink Partnrs, Needham & Company LLC, Piper Sandler, Royal Bank of Canada, SVB Leerink, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:TDOC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The #1 Crypto for 2024
InvestorPlace
Your Money is Not Safe
American Alternative